Best Biopharma Outsourcing Companies in Jiangsu, China
The 48 best Biopharma Outsourcing companies in Jiangsu, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ausco Biopharma.
Our analysis of 100 Biopharma Outsourcing companies
$10.3b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in Jiangsu
| # | Company | Last round | Disclosed funding | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Arromax Pharmatech Manufacturer of oncology, cardiovascular and diabetes generics | — | — | — | 2011 | Eric Hong CEO & GM | — | 20 patents Design and synthesis of heterocyclic small‑molecule kinase inhibitors (BTK, sodium channel, EP4). | — |
| 2 | Basilea Offers contract research, development, and manufacturing services for biologic drugs | — | — | 72 | 2002 | — | — | — | — |
| 3 | Bichal Biological Technology Researching and manufacturing of APIs & Intermediates for pharma companies | — | — | — | 2010 | Bison Zhang CEO | — | — | — |
| 4 | Bioworkshops Biologics contract development and manufacturing organization offering services for the development and… | — | — | — | 2019 | Alex Zhu CEO | Microsoft ASP.NETTengineCloudflare+6 | — | — |
| 5 | crystal pharmatech Crystal Pharmatech is a solid-state drug development firm. | — | — | 180 | 2010 | — | — | 234 patents Novel crystalline forms and salts of pharmaceutical active ingredients for improved drug properties. | — |
| 6 | Curovax Vaccine company that develops and manufactures vaccines and logistics services | — | — | 60 | 2011 | — | — | — | — |
| 7 | Jiangsu Hansoh Pharmaceutical Manufactures APIs and finished drugs | — | — | 9,432 | 1995 | Guo Xiaoman CEO & Director | JavaNginxOpenResty+4 | 1,096 patents Novel heterocyclic small‑molecule and antibody therapeutics for oncology and immune modulation | — |
| 8 | Jiangsu Hengrui Medicine R&D and manufacture of antineoplastics and surgical medicines | — | — | 15,000 | 1970 | Jerry Su CEO | — | 3,332 patents Immuno‑oncology biologics (PD‑1, TSLP antibodies) and targeted small‑molecule cancer therapies | — |
Top 12 Biopharma Outsourcing companies in Jiangsu
#1
Series C · Suzhou, Jiangsu · founded 2015$15.8Mraised▾
Developer of stem cell therapy products and human organ regenerative medicine. The company is mainly engaged in research and development of regenerative medicine, providing users with interstitial lung disease, assisted reproduction, stem cell storage and chronic obstructive pulmonary disease treatment solutions.
- Feb 2026Series C$50.6M
- Mar 2022Series B$15.8M
#2
Series C · Nanjing, Jiangsu · founded 2010 · 500 employees$107.3Mraised▾
CDMO manufacturing APIs
- Jan 2024Series C$63.3M
- Dec 2022Series B$28.6M
- Jul 2021Series B$15.5M
#3
Series D · Nantong, Jiangsu · founded 2017$406.7Mraised▾
Ausco Biopharma develops recombinant proteins. They offer services including process development and production for recombinant protein products such as antibodies and antibody fragments, clotting factor products, and vaccine products such as viral vaccines and bacterial vaccines, viral particle products.
- Jan 2022Series D$235.9M
- Mar 2021Series C$61.4M
- Jul 2020Series B$64.3M
- Jan 2019Series A$45M
#4
Series B · Suzhou, Jiangsu · founded 2018$80Mraised▾
Provider of cell & gene therapy, discovery research, analytical development, and testing services
- Aug 2022Series B$80M
#5
Series C · Suzhou, Jiangsu · founded 2018 · 100 employees$74Mraised▾
Researcher and developer of biological and pharmaceutical solutions. The company, as a contract development and manufacturing organization (CDMO), is equipped with professional technology platforms such as protein science, cell engineering, cell culture, protein purification, analytical science, formulation development, preparation technology, as well as pilot plant, GMP workshop, aseptic preparation filling line, preparation freeze-drying production line and so on, providing clients with one-stop biopharmaceutical development and production services.
- Aug 2022Series C$74M
- Dec 2020Series A—
#6
Series E · Nantong, Jiangsu · founded 2005$186.3Mraised▾
Novast Laboratories, a subsidiary of Novast Holdings focuses on the design and development of finished products and API formulations for the worldwide markets and offers contract development and manufacturing services for both generic and innovator companies. It is an US FDA-inspected generic and speciality pharmaceutical company with business units based in the United States and China. It has signed a development and supply agreement with Eli Lilly and company in 2012 to jointly develop and commercialize several branded products in the China market.Their product portfolio includes oral contraceptives, hormonal drug products and other conventional dosage forms, including high containment oncology dosage forms (HPAPIs).
- May 2020Series E$141.3M
- Jun 2012Series C$20M
- Jul 2009Series C$25M
#7
Public · Taizhou, Jiangsu · founded 2015 · 313 employees$66.3Mraised▾
Provider of drug development services to biopharma sector
- Apr 2021Series B$46.3M
- May 2020Series B—
- Aug 2019Series B$20M
#8
Series B · Suzhou, Jiangsu · founded 2009 · 843 employees$61.9Mraised▾
Suzhou Zelgen Biopharmaceuticals (Zelgen) is focusing on developing small as well as large molecules. Zelgen has two subsidiary companies, Shanghai Zelgen Pharma and Suzhou Zelgen Biosciences working on small molecules & recombinant protein drug discovery respectively. The company has developed small molecules such as Donafenib (Zepsun®), Jaktinib, ZG0320, ZG5216 and ZG0128 (few are based on drug stabilization technology). It also has four recombinant protein drugs under development, including rhThrombin(Zepning®), ZG001, ZG002, and ZG003. Donafenib is a lead molecule for late-stage cancer is in clinical trial phase III & Jaktinib is in phase I for autoimmune disease & cancer. A recombinant protein drug lead, rhThrombin is in phase I clinical trial for surgical bleeding.
- Jan 2018Series B$61.9M
#9
Series A · Suzhou, Jiangsu$15.7Mraised▾
Provider of drug research and development services for pharmaceutical sector
#10
Series A · Suzhou, Jiangsu · founded 2013$15.4Mraised▾
CRO focused on providing data analysis services
- Apr 2021Series A$15.4M
#11
Series B · Suzhou, Jiangsu · founded 2010 · 17 employees$24.5Mraised▾
Crystal Pharmatech is a technology-driven CRO which focuses on the specialized field of materials science and its applications w.r.t drug development. It helps its clients in discovering and selecting the optimal solid phase for development. It also supports all solid-state aspects of formulation studies, API process development, formulation development, regulatory, and intellectual property protection. The company offers a full range of services right from being the solid-state support arm to its clients and offering consulting services on specific issues.
- Dec 2018Series B$14.5M
- Sep 2015Series A$10M
#12
Series C · Taizhou, Jiangsu · founded 2009 · 100 employees$8.9Mraised▾
Curegen (Jiangsu) Pharmaceuticals develops and manufactures APIs as well as finished dosage forms. The company offers oral liquids of various therapeutic categories including anti-tumor, cardiovascular and cerebrovascular, gastrointestinal, perioperative, medical devices and others. The company also have portfolio of generic products.
- Sep 2020Series C$8.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Jiangsu is moving
A read on the academic research around Biotechnology in Jiangsu — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 150 papers.
- Jiangsu University60
- Jiangsu Academy of Agricultural Sciences33
- Jiangsu University of Science and Technology12
- Jiangsu Province Hospital11
- Jiangsu Cancer Hospital8
- Virus4
- Cancer research3
- Downregulation and upregulation3
- Viral replication3
- Gene3
- Oxidative stress1→3
- Gene1→3
- Gene knockdown1→3
- Agriculture5
- Mycotoxin3
- Sustainable agriculture3
- Population2
- Human health2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.